A Phase 2 interventional study of Thymoglobulin and Belatacept in Kidney Transplantation, sponsored by Bristol-Myers Squibb. Completed at 20 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-22.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Patients who undergo a kidney transplant require prolonged therapy with drugs that suppress the immune system (called immunosuppressive regimens) to stop the immune system from attacking the transplanted kidney in order to limit damage to or the possibility of rejecting the transplanted kidney. The purpose of this study is to evaluate benefits and risks of two immunosuppressive regimens (belatacept with everolimus or tacrolimus with mycophenolate mofetil) following thymoglobulin induction and rapid corticosteroid withdrawal.
Calcineurin inhibitor (CNI)
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; belatacept (infusion) regimen of 10 mg/kg i.v. on Day 1, Weeks 1, 2, 4, 8 and 12 post transplant and then a maintenance dose of 5 mg/kg every 4 weeks after 12 weeks post transplant; everolimus (tablet) daily dosing at 3.0 mg/day, 2 divided doses, starting on Day 3 dosing adjusted based on blood sample tests; methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
Drug: Thymoglobulin · Drug: Belatacept · Drug: Corticosteroids · Drug: Everolimus(EVL)
Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; tacrolimus (tablet) daily dosing beginning at 0.1 mg/kg/day, then adjusted based on blood sample tests; MMF (tablet) daily dosing between 0.5 to 2.0 g/day divided in 2 doses (up to 3 g/day if African Americans/Blacks); methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
Drug: Thymoglobulin · Drug: mycophenolate mofetil(MMF) · Drug: Corticosteroids · Drug: Tacrolimus(TAC)
Also known as: ATG
Also known as: Nulojix
Also known as: CellCept
Also known as: Methylprednisolone, Prednisone
Also known as: Certican®, Zortress®
Also known as: Prograf
Percentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6 Months
Number of Participants with Clinically-suspected biopsy-proven acute rejection (CSBPAR) at 6 Months
Time frame: 6 Months
Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6, 12 and 24 Months
Clinically-suspected biopsy-proven acute rejection (CSBPAR) at 6, 12 and 24 Months Change in the incidence of CSBPAR at 6, 12 and 24 months post transplant, in the belatacept + EVL(Treatment A) as compared to TAC + MMF (Treatment B).
Time frame: Up to 24 Months
Time to Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR).
Time to Clinically suspected biopsy proven acute rejection
Time frame: Up to 24 Months
Percentage of Participants With BANFF Grade by Severity Grades. BANFF Type (Grade) for Acute/Active Rejection
Treatment differences in the severity grades to treat all episodes of CSBPAR at 6, 12, and 24 months post-transplant. Type 1A - Cases with significant interstitial infiltration (\>25% of parenchyma affected) and foci of moderate tubulitis (\>4 mononuclear cells/Tubular cross section or group of 10 Tubular cell). Type 1B - Cases with significant interstitial infiltration (\>25% of parenchyma affected) and foci of moderate tubulitis (\>10 mononuclear cells/Tubular cross section or group of 10 Tubular cell).Type 2A - Cases with mild to moderate intimal arteritis.Type 2B - Cases with severe intimal arteritis comprising \>25% of the luminal area. Type 3 - Cases with "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (v3 with accompanying lymphocytic inflammation)
Time frame: At 6, 12 and 24 Months
Treatment Differences in Therapeutic Modalities
Treatment Received for Biopsy Proven Acute Rejection (Banff Grade IA or Higher), or Humoral (Antibody Mediated) Rejection Treatment regimen: Categorical analysis of CSBPAR episodes by treatment received.
Time frame: at 6, 12 and 24 Months
Number of Participants Who Survive With a Functioning Graft
Number of all participants who survive with a functioning graft at 6, 12 and 24 months post transplant
Time frame: At 6, 12 and 24 months
Number of Participants Deaths Post Transplant
Number of participant deaths at 6, 12 and 24 months post transplant
Time frame: up to 24 months
Number of Participants Who Experience Graft Loss Post Transplant
Number of all participants who experience graft loss at 6, 12 and 24 months post transplant
Time frame: At 6, 12 and 24 months
Time to Event: Graft Loss and Death
The Number of days to participant Graft Loss and death for any reason
Time frame: Up to 728 Days
Absolute Calculated Glomerular Filtration Rate (cGFR): Mean
Absolute (mean and median) cGFR values at 3, 6, 12 and 24 months post-transplant, as determined from the 4-variable Modification of Diet in Renal Disease (MDRD) formula
Time frame: Up 24 Months post-transplant
Median Calculated Glomerular Filtration Rate (cGFR)
Median cGFR values at 3, 6, 12 and 24 months post-transplant, as determined from the 4-variable Modification of Diet in Renal Disease (MDRD) formula
Time frame: Up 24 Months post-transplant
Mean Change From Month 3 in cGFR
The mean change from Month 3 cGFR at 3, 6, 12 and 24 months post-transplant
Time frame: Up 24 Months post-transplant
Urine Protein Creatinine Ratio (UPr/Cr)
Urine protein to creatinine ratio (UPr/Cr) at 3, 6, 12 and 24 months post-transplant.
Time frame: Up 24 Months post-transplant
Percentage of Participants With Donor Specific Anti-HLA Antibodies (DSA)
Percentage of participants with, and titers of pre-existing (pre-transplant) DSA on Day 1 (pre-transplant, pre-dose), and at Months 12 and 24 posttransplant
Time frame: Up to 24 Months
Percentage of Participants With De Novo Donor Specific Anti-HLA Antibodies (DSA)
Characterization of any de novo DSA detected by IgM and IgG subclasses, and by the presence or absence of complement fixing properties.
Time frame: Up to 24 Months
Percentage of Participants With Adverse Events (AEs)
Percentage of participants with AEs up to 24 months post-transplant
Time frame: Up to 24 months Post-Transplant
Percentage of Participants With Serious Adverse Events (SAEs)
Percentage of participants with SAEs up to 24 months post-transplant
Time frame: Up to 24 months Post-Transplant
Percentage of Participants With Events of Special Interest (ESIs)
Percentage of participants which have one of the following events of special interest: Serious Infections Post-Transplant Lymphoproliferative Disorder (PTLD) Progressive multifocal leukoencephalopathy (PML) Malignancies (Other than PTLD) including non-melanoma skin carcinomas (Malignancies) Tuberculosis Infections Central Nervous System (CNS) Infections Viral Infections Infusion Related reactions within 24 hours since belatacept infusion
Time frame: Up to 24 Months
Percentage of Particpants With Laboratory Test Abnormalities (LTAs)
Percentage of participants with laboratory tests with marked laboratory abnormalities
Time frame: At 24 Months
Mean and Mean Change From Baseline in Blood Glucose
Mean fasting blood glucose levels, and mean changes from baseline values at Months 6, 12 and 24 months post- transplant
Time frame: Up to 24 months
Mean and Mean Change From Baseline in Whole Blood HbA1c
Mean whole blood HbA1C concentrations, and mean changes from baseline values at Months 6, 12 and 24 months post-transplant.
Time frame: Up to 24 months
Percentage of Participants With New Onset Diabetes After Transplant
Percentage of participants with New Onset Diabetes After Transplantation (NODAT) at 6, 12, and 24 months post-transplant.
Time frame: up to 24 months
Absolute Values of Blood Pressure: Mean
Absolute (mean and median) values for SBP and DBP at 3, 6, 12 and 24 months posttransplant;
Time frame: Up to 24 Months
Absolute Values of Blood Pressure: Median
Absolute (mean and median) values for SBP and DBP at 3, 6, 12 and 24 months posttransplant;
Time frame: Up to 24 Months
Mean Changes From Baseline Values for Blood Pressure
Mean changes from baseline values for SBP and DBP at 6, 12 and 24 months post-transplant
Time frame: Up to 24 Months
Absolute Values of Fasting Lipid Values: Mean
Absolute (mean and median) values at 3, 6, 12 and 24 months post-transplant for the following: Serum total cholesterol (TC) Serum high density lipoprotein (HDL) cholesterol Serum low density lipoprotein (LDL) cholesterol Serum triglycerides (TG)
Time frame: Up to 24 Months
Absolute Values of Fasting Lipid Values: Median
Absolute (mean and median) values at 3, 6, 12 and 24 months post-transplant for the following: Serum total cholesterol (TC) Serum high density lipoprotein (HDL) cholesterol Serum low density lipoprotein (LDL) cholesterol Serum triglycerides (TG)
Time frame: Up to 24 Months
Mean Changes From Baseline Values of Lipid Values
Mean changes from baseline values in the following: Serum total cholesterol (TC) Serum high density lipoprotein (HDL) cholesterol Serum low density lipoprotein (LDL) cholesterol Serum triglycerides (TG)
Time frame: at months 12 and 24
| Milestone | Treatment A | Treatment B |
|---|---|---|
| Started | 26 | 32 |
| Completed | 23 | 26 |
| Not completed | 3 | 6 |
| Withdrew: Discontinued study treatment | 0 | 3 |
| Withdrew: Withdrew consent | 1 | 1 |
| Withdrew: Adverse event | 2 | 2 |
Number of Participants with Clinically-suspected biopsy-proven acute rejection (CSBPAR) at 6 Months
| Percentage of participants | Treatment A | Treatment B |
|---|---|---|
| Percentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6 Months | 7.7 (0.9 to 25.1) | 9.4 (2.0 to 25.0) |
Clinically-suspected biopsy-proven acute rejection (CSBPAR) at 6, 12 and 24 Months Change in the incidence of CSBPAR at 6, 12 and 24 months post transplant, in the belatacept + EVL(Treatment A) as compared to TAC + MMF (Treatment B).
| Percentage of CSBPAR | Treatment A | Treatment B |
|---|---|---|
| CSBPAR at 6 Months | 7.7 (0.9 to 25.1) | 9.4 (2.0 to 25.0) |
| CSBPAR at 12 months | 11.5 (2.4 to 30.2) | 12.5 (3.5 to 29.0) |
| CSBPAR at 24 Months | 15.4 (4.4 to 34.9) | 12.5 (3.5 to 29.0) |
Time to Clinically suspected biopsy proven acute rejection
| Months | Treatment A | Treatment B |
|---|---|---|
| Time to Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR). | NA (NA to NA) | NA (NA to NA) |
Treatment differences in the severity grades to treat all episodes of CSBPAR at 6, 12, and 24 months post-transplant. Type 1A - Cases with significant interstitial infiltration (\>25% of parenchyma affected) and foci of moderate tubulitis (\>4 mononuclear cells/Tubular cross section or group of 10 Tubular cell). Type 1B - Cases with significant interstitial infiltration (\>25% of parenchyma affected) and foci of moderate tubulitis (\>10 mononuclear cells/Tubular cross section or group of 10 Tubular cell).Type 2A - Cases with mild to moderate intimal arteritis.Type 2B - Cases with severe intimal arteritis comprising \>25% of the luminal area. Type 3 - Cases with "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (v3 with accompanying lymphocytic inflammation)
| Percentage of Participants | Treatment A | Treatment B |
|---|---|---|
| 6 Months: Mild Acute (1A) | 3.8 | 0 |
| 6 Months: Mild Acute (1B) | 0 | 3.1 |
| 6 Months: Moderate Acute (2A) | 7.7 | 6.3 |
| 6 Months: Moderate Acute (2B) | 0 | 0 |
| 6 Months: Severe Acute | 0 | 0 |
| 12 Months: Mild Acute (1A) | 7.7 | 3.1 |
| 12 Months: Mild Acute (1B) | 0 | 3.1 |
| 12 Months: Moderate Acute (2A) | 7.7 | 6.3 |
| 12 Months: Moderate Acute (2B) | 0 | 0 |
| 12 Months: Severe Acute | 0 | 0 |
| 24 Months: Mild Acute (1A) | 11.5 | 3.1 |
| 24 Months: Mild Acute (1B) | 0 | 3.1 |
| 24 Months: Moderate Acute (2A) | 7.7 | 6.3 |
| 24 Months: Moderate Acute (2B) | 0 | 0 |
| 24 Months: Severe Acute | 0 | 0 |
Treatment Received for Biopsy Proven Acute Rejection (Banff Grade IA or Higher), or Humoral (Antibody Mediated) Rejection Treatment regimen: Categorical analysis of CSBPAR episodes by treatment received.
| Percentage of participants with CSBPARs | Treatment A | Treatment B |
|---|---|---|
| Corticosteroids (6 months) | 7.7 | 9.4 |
| Lymphocyte depleting agent (6 months) | 0 | 6.3 |
| Plasmapheresis (6 months) | 0 | 0 |
| IVIG (6 months) | 0 | 3.1 |
| Rituximab (6 months) | 0 | 0 |
| Corticosteroids (12 months) | 15.4 | 12.5 |
| Lymphocyte depleting agent (12 months) | 3.8 | 6.3 |
| Plasmapheresis (12 months) | 0 | 0 |
| IVIG (12 months) | 0 | 3.1 |
| Rituximab (12 months) | 0 | 0 |
| Corticosteroids (24 months) | 19.2 | 12.5 |
| Lymphocyte depleting agent (24 months) | 3.8 | 6.3 |
| Plasmapheresis (24 months) | 0 | 0 |
| IVIG (24 months) | 0 | 3.1 |
| Rituximab (24 months) | 0 | 0 |
Number of all participants who survive with a functioning graft at 6, 12 and 24 months post transplant
| Participants | Treatment A | Treatment B |
|---|---|---|
| At 6 Months | 25 | 31 |
| At 12 Months | 25 | 31 |
| At 24 Months | 25 | 31 |
Number of participant deaths at 6, 12 and 24 months post transplant
| Participants | Treatment A | Treatment B |
|---|---|---|
| At 6 Months | 0 | 0 |
| At 12 Months | 0 | 0 |
| At 24 Months | 0 | 0 |
Number of all participants who experience graft loss at 6, 12 and 24 months post transplant
| Participants | Treatment A | Treatment B |
|---|---|---|
| At 6 Months | 1 | 1 |
| At 12 Months | 1 | 1 |
| At 24 Months | 1 | 1 |
The Number of days to participant Graft Loss and death for any reason
| Days | Treatment A | Treatment B |
|---|---|---|
| Graft Loss | 107 | 2 |
Absolute (mean and median) cGFR values at 3, 6, 12 and 24 months post-transplant, as determined from the 4-variable Modification of Diet in Renal Disease (MDRD) formula
| mL/min/1.73 m^2 | Treatment A | Treatment B |
|---|---|---|
| At 3 Months | 69.2 (60.2 to 78.3) | 62.2 (55.3 to 69.1) |
| At 6 Months | 66.0 (55.8 to 76.2) | 63.9 (56.2 to 71.5) |
| At 12 Months | 66.2 (56.9 to 75.4) | 62.0 (53.4 to 70.6) |
| At 24 Months | 71.8 (62.5 to 81.0) | 68.7 (59.2 to 78.2) |
Median cGFR values at 3, 6, 12 and 24 months post-transplant, as determined from the 4-variable Modification of Diet in Renal Disease (MDRD) formula
| mL/min/1.73 m^2 | Treatment A | Treatment B |
|---|---|---|
| At 3 Months | 64.0 (52.0 to 80.0) | 62.0 (55.0 to 79.0) |
| At 6 Months | 64.0 (56.0 to 79.0) | 67.0 (55.0 to 75.0) |
| At 12 Months | 66.0 (58.0 to 77.0) | 62.5 (47.5 to 74.0) |
| At 24 Months | 73.5 (59.5 to 84.5) | 68.0 (56.0 to 82.0) |
The mean change from Month 3 cGFR at 3, 6, 12 and 24 months post-transplant
| mL/min/1.73 m^2 | Treatment A | Treatment B |
|---|---|---|
| At 3 Months | 0 (0 to 0) | 0 (0 to 0) |
| At 6 Months | -3.2 (-10.9 to 4.5) | 2.8 (-0.2 to 5.8) |
| At 12 Months | -3.1 (-12.6 to 6.5) | 1.4 (-3.3 to 6.0) |
| At 24 Months | 3.1 (-4.2 to 10.4) | 6.3 (-0.6 to 13.2) |
Urine protein to creatinine ratio (UPr/Cr) at 3, 6, 12 and 24 months post-transplant.
| mg Protein/mg Creatinine | Treatment A | Treatment B |
|---|---|---|
| At 3 Months | 0.3146 (0.1985 to 0.4307) | 0.1412 (0.1097 to 0.1726) |
| At 6 Months | 0.3896 (0.2326 to 0.5466) | 0.1461 (0.1203 to 0.1720) |
| At 12 Months | 0.2835 (0.1648 to 0.4021) | 0.1849 (0.1041 to 0.2658) |
| At 24 Months | 0.3940 (0.2199 to 0.5680) | 0.1685 (0.1174 to 0.2195) |
Percentage of participants with, and titers of pre-existing (pre-transplant) DSA on Day 1 (pre-transplant, pre-dose), and at Months 12 and 24 posttransplant
| Percentage of Participants | Treatment A | Treatment B |
|---|---|---|
| Baseline Class 1 DSA | 10 | 0 |
| Baseline Class 2 DSA | 0 | 0 |
| Baseline Both Class 1 and 2 DSA | 0 | 0 |
| 12 Month Class 1 DSA | 8.00 | 0 |
| 12 Month Class 2 DSA | 0 | 3.03 |
| 12 Month Both Class 1 and 2 DSA | 0 | 0 |
| 24 Month Class 1 DSA | 8.00 | 3.03 |
| 24 Month Class 2 DSA | 0 | 3.03 |
| 24 Month Both Class 1 and 2 DSA | 0 | 0 |
Characterization of any de novo DSA detected by IgM and IgG subclasses, and by the presence or absence of complement fixing properties.
| Percentage | Treatment A | Treatment B |
|---|---|---|
| Baseline Class 1 DSA | 10 | 0 |
| Baseline Class 2 DSA | 0 | 0 |
| Baseline Both Class 1 and 2 DSA | 0 | 0 |
| De Novo 12 Month Class 1 DSA | 0 | 0 |
| De Novo 12 Month Class 2 DSA | 0 | 0 |
| De Novo 12 Month Both Class 1 and 2 DSA | 0 | 0 |
| De Novo 24 Month Class 1 DSA | 0 | 3.45 |
| De Novo 24 Month Class 2 DSA | 0 | 0 |
| De Novo 24 Month Both Class 1 and 2 DSA | 0 | 0 |
Percentage of participants with AEs up to 24 months post-transplant
| Percentage of participants with AEs | Treatment A | Treatment B |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 100.0 | 97.0 |
Percentage of participants with SAEs up to 24 months post-transplant
| Percentage of participants with SAEs | Treatment A | Treatment B |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) | 52.0 | 60.6 |
Percentage of participants which have one of the following events of special interest: Serious Infections Post-Transplant Lymphoproliferative Disorder (PTLD) Progressive multifocal leukoencephalopathy (PML) Malignancies (Other than PTLD) including non-melanoma skin carcinomas (Malignancies) Tuberculosis Infections Central Nervous System (CNS) Infections Viral Infections Infusion Related reactions within 24 hours since belatacept infusion
| Percentage of participants with ESIs | Treatment A | Treatment B |
|---|---|---|
| Serious Infections | 16 | 15.2 |
| PTLD | 4.0 | 3.0 |
| PML | 0 | 0 |
| Malignancies | 4.0 | 3.0 |
| TB | 0 | 0 |
| CNS Infections | 0 | 0 |
| Viral Infections | 0 | 0 |
| Infusion Related Reactions | 1 | 0 |
Percentage of participants with laboratory tests with marked laboratory abnormalities
| Percentage of participants | Treatment A | Treatment B |
|---|---|---|
| Hemoglobin (Low) | 12.0 | 6.1 |
| Leukocytes (low) | 0 | 3.0 |
| Lymphocyte (Absolute) (low) | 84.0 | 69.7 |
| Neutrophils (Absolute) (low) | 0 | 3.0 |
| Aspartate Aminotransferase (High) | 4.0 | 0 |
| Creatinine (High) | 16.0 | 3.0 |
| Inorganic Phosphorus (low) | 24.0 | 12.1 |
| Potassium (high) | 4.0 | 0 |
| Sodium (low) | 4.0 | 0 |
| Albumin (low) | 0 | 3.0 |
| Glucose (high) | 8.0 | 12.1 |
| Triglycerides (high) | 12.0 | 0 |
| Uric Acid (high) | 8.0 | 0 |
Mean fasting blood glucose levels, and mean changes from baseline values at Months 6, 12 and 24 months post- transplant
| mg/dL | Treatment A | Treatment B |
|---|---|---|
| Mean Value at 6 months | 107.2 (86.6 to 127.8) | 107.2 (93.8 to 120.7) |
| Change from baseline at 6 months | 4.9 (-5.8 to 15.7) | 4.8 (-17.6 to 27.2) |
| Mean Value at 12 months | 101.1 (85.3 to 117.0) | 127.5 (99.2 to 155.8) |
| Change from baseline at 12 months | -1.3 (-24.7 to 22.1) | 20.6 (0.4 to 40.8) |
| Mean Value at 24 months | 127.5 (93.7 to 161.4) | 111.8 (87.1 to 136.5) |
| Change from baseline at 24 months | 22.3 (-15.7 to 60.3) | 15.0 (-3.2 to 33.2) |
Mean whole blood HbA1C concentrations, and mean changes from baseline values at Months 6, 12 and 24 months post-transplant.
| mg/dL | Treatment A | Treatment B |
|---|---|---|
| Mean Value at 6 months | 6.11 (5.47 to 6.75) | 6.13 (5.44 to 6.82) |
| Change from baseline at 6 months | 0.34 (0.06 to 0.62) | 0.48 (0.04 to 0.91) |
| Mean Value at 12 months | 6.18 (5.42 to 6.93) | 6.21 (5.50 to 6.92) |
| Change from baseline at 12 months | 0.47 (-0.00 to 0.95) | 0.32 (-0.17 to 0.81) |
| Mean Value at 24 months | 6.24 (5.27 to 7.20) | 6.29 (5.38 to 7.20) |
| Change from baseline at 24 months | 0.66 (-0.05 to 1.37) | 0.41 (-0.13 to 0.95) |
Percentage of participants with New Onset Diabetes After Transplantation (NODAT) at 6, 12, and 24 months post-transplant.
| Percentage of participants | Treatment A | Treatment B |
|---|---|---|
| Up to 6 Months | 11.5 (2.4 to 30.2) | 6.3 (0.8 to 20.8) |
| Up to 12 Months | 11.5 (2.4 to 30.2) | 6.3 (0.8 to 20.8) |
| Up to 24 Months | 15.4 (4.4 to 34.9) | 12.5 (3.5 to 29.0) |
Absolute (mean and median) values for SBP and DBP at 3, 6, 12 and 24 months posttransplant;
| mmHg | Treatment A | Treatment B |
|---|---|---|
| Diastolic Month 3 | 78.7 (74.2 to 83.2) | 77.7 (74.0 to 81.3) |
| Systolic Month 3 | 134.2 (126.9 to 141.6) | 131.0 (124.9 to 137.0) |
| Diastolic Month 6 | 77.4 (73.6 to 81.3) | 79.4 (76.0 to 82.9) |
| Systolic Month 6 | 128.1 (121.8 to 134.5) | 133.0 (127.2 to 138.8) |
| Diastolic Month 12 | 78.7 (74.6 to 82.9) | 80.1 (76.4 to 83.8) |
| Systolic Month 12 | 131.0 (125.6 to 136.4) | 131.0 (123.4 to 138.7) |
| Diastolic Month 24 | 78.1 (74.2 to 81.9) | 78.5 (74.3 to 82.8) |
| Systolic Month 24 | 130.9 (125.2 to 136.5) | 131.7 (125.2 to 138.2) |
Absolute (mean and median) values for SBP and DBP at 3, 6, 12 and 24 months posttransplant;
| mmHg | Treatment A | Treatment B |
|---|---|---|
| Diastolic Month 3 | 78.5 (70.0 to 88.0) | 80.0 (70.0 to 84.0) |
| Systolic Month 3 | 135.5 (127.0 to 144.0) | 131.0 (122.0 to 138.0) |
| Diastolic Month 6 | 75.5 (70.5 to 83.0) | 80.0 (71.0 to 85.5) |
| Systolic Month 6 | 127.0 (114.5 to 136.5) | 131.0 (124.0 to 142.5) |
| Diastolic Month 12 | 77.0 (71.5 to 86.0) | 81.0 (72.0 to 88.0) |
| Systolic Month 12 | 130.0 (119.0 to 142.0) | 126.0 (115.0 to 146.0) |
| Diastolic Month 24 | 78.0 (71.0 to 86.0) | 79.0 (69.5 to 85.0) |
| Systolic Month 24 | 130.0 (122.0 to 142.0) | 130.0 (121.5 to 139.0) |
Mean changes from baseline values for SBP and DBP at 6, 12 and 24 months post-transplant
| mmHg | Treatment A | Treatment B |
|---|---|---|
| Diastolic Month 6 | 1.0 (-4.7 to 6.7) | 4.8 (-1.2 to 10.8) |
| Systolic Month 6 | -4.0 (-13.9 to 5.9) | -0.7 (-10.0 to 8.7) |
| Diastolic Month 12 | 2.3 (-4.0 to 8.6) | 5.4 (-1.0 to 11.7) |
| Systolic Month 12 | -1.1 (-9.6 to 7.4) | -3.2 (-14.7 to 8.3) |
| Diastolic Month 24 | 0.9 (-5.5 to 7.3) | 2.1 (-3.9 to 8.1) |
| Systolic Month 24 | -2.3 (-12.2 to 7.6) | -4.2 (-14.4 to 6.0) |
Absolute (mean and median) values at 3, 6, 12 and 24 months post-transplant for the following: Serum total cholesterol (TC) Serum high density lipoprotein (HDL) cholesterol Serum low density lipoprotein (LDL) cholesterol Serum triglycerides (TG)
| mg/dL | Treatment A | Treatment B |
|---|---|---|
| TC Month 3 | 181.2 (157.8 to 204.7) | 174.4 (154.8 to 194.1) |
| TC Month 6 | 197.7 (177.9 to 217.4) | 175 (158.8 to 191.6) |
| TC Month 12 | 189.0 (171.7 to 206.3) | 169.9 (153.8 to 186.0) |
| TC Month 24 | 193.2 (172.1 to 214.2) | 168.2 (152.9 to 183.4) |
| HDL Month 3 | 50.6 (43.5 to 57.6) | 50.4 (43.9 to 56.9) |
| HDL Month 6 | 46.4 (41.3 to 51.5) | 53.9 (45.9 to 61.8) |
| HDL Month 12 | 49.4 (44.0 to 54.8) | 49.6 (42.5 to 56.6) |
| HDL Month 24 | 50.1 (44.7 to 55.5) | 51.3 (43.0 to 59.6) |
| LDL Month 3 | 96.9 (77.9 to 115.9) | 96.5 (80.3 to 112.6) |
| LDL Month 6 | 115.2 (98.1 to 132.3) | 93.7 (79.2 to 108.2) |
| LDL Month 12 | 107.5 (92.8 to 122.2) | 88.0 (74.3 to 101.8) |
| LDL Month 24 | 97.9 (81.6 to 114.2) | 91.5 (75.4 to 107.6) |
| TG Month 3 | 171.6 (118.1 to 225.0) | 137.8 (106.6 to 168.9) |
| TG Month 6 | 180.0 (140.2 to 219.7) | 138.3 (108.0 to 168.5) |
| TG Month 12 | 162.4 (132.2 to 192.6) | 161.3 (126.4 to 196.1) |
| TG Month 24 | 263.4 (131.2 to 395.5) | 145.0 (99.8 to 190.2) |
Absolute (mean and median) values at 3, 6, 12 and 24 months post-transplant for the following: Serum total cholesterol (TC) Serum high density lipoprotein (HDL) cholesterol Serum low density lipoprotein (LDL) cholesterol Serum triglycerides (TG)
| mg/dL | Treatment A | Treatment B |
|---|---|---|
| TC Month 3 | 167.0 (160.0 to 213.0) | 173.0 (146.0 to 197.0) |
| TC Month 6 | 187.0 (170.5 to 226.5) | 178.0 (146.0 to 199.0) |
| TC Month 12 | 184.0 (166.0 to 213.0) | 171.5 (146.5 to 193.5) |
| TC Month 24 | 193.0 (166.0 to 206.0) | 166.0 (137.0 to 201.0) |
| HDL Month 3 | 45.0 (39.0 to 62.0) | 49.0 (38.0 to 63.0) |
| HDL Month 6 | 45.5 (39.0 to 51.0) | 49.0 (37.0 to 68.0) |
| HDL Month 12 | 50.0 (40.0 to 58.0) | 47.0 (37.0 to 61.0) |
| HDL Month 24 | 49.0 (43.0 to 58.0) | 49.0 (35.0 to 71.0) |
| LDL Month 3 | 89.0 (74.0 to 127.0) | 95.0 (75.0 to 116.0) |
| LDL Month 6 | 99.5 (85.5 to 143.0) | 100.0 (66.0 to 115.0) |
| LDL Month 12 | 104.0 (85.0 to 128.0) | 91.5 (65.0 to 109.0) |
| LDL Month 24 | 103.5 (74.0 to 121.0) | 86.0 (70.0 to 119.0) |
| TG Month 3 | 147.0 (107.0 to 195.0) | 128.0 (81.0 to 174.0) |
| TG Month 6 | 157.5 (113.5 to 245.5) | 126.0 (85.0 to 194.0) |
| TG Month 12 | 154.0 (100.0 to 230.0) | 130.0 (106.0 to 202.0) |
| TG Month 24 | 159.0 (137.0 to 284.0) | 114.0 (80.0 to 174.0) |
Mean changes from baseline values in the following: Serum total cholesterol (TC) Serum high density lipoprotein (HDL) cholesterol Serum low density lipoprotein (LDL) cholesterol Serum triglycerides (TG)
| mg/dL | Treatment A | Treatment B |
|---|---|---|
| TC Month 12 | 25.7 (3.5 to 47.9) | -2.8 (-41.5 to 35.8) |
| TC Month 24 | 26.6 (4.0 to 49.1) | 10.0 (-9.9 to 29.9) |
| HDL Month 12 | 5.4 (-0.3 to 11.0) | 1.9 (-3.7 to 7.5) |
| HDL Month 24 | 6.2 (0.7 to 11.6) | 4.8 (-2.2 to 11.9) |
| LDL Month 12 | 25.7 (7.9 to 43.4) | 10.8 (-10.8 to 32.4) |
| LDL Month 24 | 17.4 (0.0 to 34.7) | 15.7 (-4.4 to 35.7) |
| TG Month 12 | 3.3 (-26.0 to 32.5) | -86.1 (-288.9 to 116.7) |
| TG Month 24 | 106.8 (-32.6 to 246.2) | -13.6 (-73.8 to 46.5) |
Collected over Up to 24 months after last treatment dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BELA+EVL | 0/25 (0%) | 13/25 (52%) | 25/25 (100%) |
| TAC+MMF | 0/33 (0%) | 20/33 (60.6%) | 30/33 (90.9%) |
| Event | BELA+EVL | TAC+MMF |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/25 | 4/33 |
| Urinary tract infectionInfections and infestations | 3/25 | 0/33 |
| Blood creatinine increasedInvestigations | 1/25 | 3/33 |
| Cholecystitis acuteHepatobiliary disorders | 2/25 | 0/33 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/25 | 2/33 |
| Acute kidney injuryRenal and urinary disorders | 0/25 | 2/33 |
| AnaemiaBlood and lymphatic system disorders | 1/25 | 1/33 |
| PancytopeniaBlood and lymphatic system disorders | 1/25 | 0/33 |
| Atrial fibrillationCardiac disorders | 1/25 | 1/33 |
| AscitesGastrointestinal disorders | 1/25 | 0/33 |
| Event | BELA+EVL | TAC+MMF |
|---|---|---|
| Mouth ulcerationGastrointestinal disorders | 10/25 | 0/33 |
| NauseaGastrointestinal disorders | 5/25 | 13/33 |
| HypophosphataemiaMetabolism and nutrition disorders | 9/25 | 8/33 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/25 | 11/33 |
| LeukopeniaBlood and lymphatic system disorders | 8/25 | 7/33 |
| ConstipationGastrointestinal disorders | 5/25 | 10/33 |
| DiarrhoeaGastrointestinal disorders | 4/25 | 10/33 |
| HypokalaemiaMetabolism and nutrition disorders | 7/25 | 3/33 |
| HypomagnesaemiaMetabolism and nutrition disorders | 2/25 | 8/33 |
| HypertensionVascular disorders | 6/25 | 8/33 |
Randomized, Transplanted and Treated Population (ITT)
| Age, Continuous(Years) | Treatment A | Treatment B | Total |
|---|---|---|---|
| Mean | 51.7 ± 12.8 | 50.8 ± 10.9 | 51.2 ± 11.7 |
| Age, Customized(Participants) | Treatment A | Treatment B | Total |
|---|---|---|---|
| < 65 | 22 | 28 | 50 |
| ≥ 65 | 4 | 4 | 8 |
| Sex: Female, Male(Participants) | Treatment A | Treatment B | Total |
|---|---|---|---|
| Female | 5 | 9 | 14 |
| Male | 21 | 23 | 44 |
| Race (NIH/OMB)(Participants) | Treatment A | Treatment B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 6 | 9 |
| White | 23 | 21 | 44 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in May 2019, 40 months.
Results were first posted in Jun 2021, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept